paris saponin vii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Paris saponin VII: has antineoplastic activity; isolated from Trillium tschonoskii; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Flora	Rank	Flora Definition	Family	Family Definition
Trillium	genus	A plant genus of the family Melanthiaceae that is a short plant with a distinct whorl of 3 broad leaves.[MeSH]	Melanthiaceae	A family in the order Liliales, of bulbous or rhizomatous woodland and alpine perennial herbs.[MeSH]

Cross-References

ID Source	ID
PubMed CID	176233
MeSH ID	M000604204

Synonyms (15)

Synonym
pennogenin tetraglycoside
68124-04-9
S9156
beta-d-glucopyranoside, (3beta,25r)-17-hydroxyspirost-5-en-3-yl o-6-deoxy-alpha-l-mannopyranosyl-(1-2)-o-(o-6-deoxy-alpha-l-mannopyranosyl-(1-4)-6-deoxy-alpha-l-mannopyranosyl-(1-4))-
chonglou saponin vii
dioscinin
AKOS032946455
paris saponin-vii
BS-14117
CS-0023885
paris saponin vii
HY-N3584
CCG-270613
paris vii
DTXSID101318576

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (5.56)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (5.56)	29.6817
2010's	8 (44.44)	24.3611
2020's	8 (44.44)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.82 (24.57)
Research Supply Index	2.94 (2.92)
Research Growth Index	5.77 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	18 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
2,3,4,5-tetrahydroxypentanal [no description available]	2.31	1	hydroxyaldehyde; pentose; polyol
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	2.13	1	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
tricalcium phosphate tricalcium phosphate: a form of tricalcium phosphate used as bioceramic bone replacement material; see also records for alpha-tricalcium phosphate, beta-tricalcium phosphate, calcium phosphate; apatitic tricalcium phosphate Ca9(HPO4)(PO4)5(OH) is the calcium orthophosphate leading to beta tricalcium phosphate Ca3(PO4)2 (b-TCP). calcium phosphate : A calcium salt composed of calcium and phosphate/diphosphate ions; present in milk and used for the mineralisation of calcified tissues.	2.31	1	calcium phosphate
diosgenin [no description available]	2.13	1	3beta-sterol; hexacyclic triterpenoid; sapogenin; spiroketal	antineoplastic agent; antiviral agent; apoptosis inducer; metabolite
gefitinib [no description available]	2.13	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
inositol 1,4,5-trisphosphate Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.	2.07	1	myo-inositol trisphosphate	mouse metabolite
pectins Pectins: High molecular weight polysaccharides present in the cell walls of all plants. Pectins cement cell walls together. They are used as emulsifiers and stabilizers in the food industry. They have been tried for a variety of therapeutic uses including as antidiarrheals, where they are now generally considered ineffective, and in the treatment of hypercholesterolemia.. alpha-D-galacturonic acid : The alpha-anomer of D-galacturonic acid.	2.31	1	D-galactopyranuronic acid
glycosides [no description available]	2.04	1
beta-escin [no description available]	4.2	14
formosanin c formosanin C: diosgenin saponin from Paris formosana; structure given in first source	2.13	1

Condition	Relationship Strength	Studies
Breast Cancer [description not available]	7.69	2
Breast Neoplasms Tumors or cancer of the human BREAST.	2.69	2
Cancer of Colon [description not available]	2.31	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.31	1
Carcinoma, Non-Small Cell Lung [description not available]	2.69	2
Cancer of Lung [description not available]	2.9	3
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.69	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.9	3
Di Guglielmo Disease [description not available]	2.31	1
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	2.31	1
Colorectal Cancer [description not available]	7.21	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.21	1
Lung Adenocarcinoma [description not available]	2.13	1
Adenocarcinoma, Basal Cell [description not available]	2.13	1
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	2.13	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.13	1
Bone Cancer [description not available]	2.13	1
Osteogenic Sarcoma [description not available]	2.13	1
Invasiveness, Neoplasm [description not available]	2.13	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	2.13	1
Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)	7.13	1

chemdatabank.com